# Denosumab in Primary Hyperparathyroidism

> **NCT01558115** · PHASE4 · TERMINATED · sponsor: **Columbia University** · enrollment: 8 (actual)

## Conditions studied

- Primary Hyperparathyroidism

## Interventions

- **DRUG:** Denosumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01558115
- **Lead sponsor:** Columbia University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-01
- **Primary completion:** 2014-10
- **Final completion:** 2014-10
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Poor enrollment
- **Last updated:** 2022-11-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01558115

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01558115, "Denosumab in Primary Hyperparathyroidism". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01558115. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*